Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(100%)

Phase Distribution

Ph phase_3
1
50%
Ph phase_2
1
50%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Terminated(2)

Detailed Status

Terminated2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (50.0%)
Phase 31 (50.0%)

Trials by Status

terminated2100%

Recent Activity

0 active trials
Showing 2 of 2
terminatedphase_2

Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

NCT00237536
terminatedphase_3

Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

NCT00435448

Clinical Trials (2)

Showing 2 of 2 trials
NCT00237536Phase 2

Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

Terminated
NCT00435448Phase 3

Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

Terminated

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2